Healthcare Industry News: bone graft
News Release - June 1, 2010
RepRegen Reports Data from an In Vivo Study of StronBone Bone Graft Substitute - the First Product from the Company's Platform to Repair and Regenerate Hard Tissue, such as BoneLONDON--(HSMN NewsFeed)--RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that three-month data from an in vivo study of its StronBone™ bioactive glass with Strontium demonstrated that it can generate bone quality in and around defects that appears by analytical tests to be significantly superior to a standard bone void filler in the control defect.
Specifically, the three-month data demonstrated that:
- The bone in the defect was significantly stiffer—68%—in the StronBone defect than in the control defect; and,
- The bone in the defect was significantly denser—41%—in the StronBone defect than in the control defect.
The in vivo and analytical study was conducted at the Institute of Orthopaedics and Musculoskeletal Science at University College London (UCL) by principal investigator Professor Allen Goodship, Professor of Orthopaedic Sciences and Director of the Institute, who will be submitting the data for publication.
“The results of this study underscore why we believe our platform has the potential to dramatically enhance the repair and regeneration of hard tissue, such as bone,” said Ian Brown, RepRegen’s CEO. “These results also fortify our plans to begin commercialization of the first product from our hard tissue platform in 2010.”
“The worldwide market for the orthopaedic biomaterials sector is expected to soar to $8.8 billion by 2012,” added RepRegen’s Chairman, Dr. Stephen Rietiker. “But of keen interest to RepRegen is not only that this sector is enormous and growing rapidly but also that it is extremely fragmented. Consequently, we expect that RepRegen will have numerous sales and out-licensing opportunities.”
Earlier this year, an in vitro study presented at the 56th Annual Meeting of the Orthopaedic Research Society (ORS) demonstrated that RepRegen’s patented Strontium-based bioactive glass platform enhances cellular attraction of osteoblasts to the matrix.
About RepRegen™ Ltd.
RepRegen™ Ltd. is a medical device company that uses patented repair and regeneration technology platforms designed to mend and regrow hard tissue such as bone and soft tissue such as cartilage. A spin-out from Imperial Innovations plc and headquartered within the Imperial College Incubator, RepRegen is poised to commercialize the initial product of its hard tissue repair and regeneration platform: StronBone™ bone graft Substitute. Other products on the hard tissue repair and regeneration runway are targeted for orthopaedic (trauma, spine) and craniomaxillofacial applications. The one-of-a-kind properties of RepRegen’s platforms are designed to enable faster and superior tissue repair and regeneration. The Company’s ‘smart’ biomaterials are designed to support and enhance natural cellular growth and tissue regeneration in vivo. These unrivaled materials are comprised of bioactive ceramics or biomimetic fibrous polymer scaffolds. A major RepRegen materials science innovation is the use of Strontium, which boosts performance of bioceramics for bone repair. Both of RepRegen’s platforms — the hard and the soft tissue technologies — include a portfolio of new and unique products with performance characteristics that are designed to yield competitive advantages, including (1) Enhanced cellular growth properties for better and faster healing; and (2) Diversified structures tailored for a variety of porosities and configurations for specific applications.
NOTE: StronBone™ bone graft Substitute is an investigational device in the USA and limited by federal law to investigational use only. In the EU, StronBone™ bone graft Substitute is awaiting CE Mark approval.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.